Biotech company Axoltis Pharma has raised €18 million to accelerate the development of an amyotrophic lateral sclerosis (ALS) drug candidate.  The closure of a Series A financing round will enable Axoltis to develop lead candidate NX210x, currently in Phase II clinical trials in patients with ALS.  The financing round was co-led by FIDAT Ventures and Cenitz with support from Agile Capital Market, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!